Table 2 Transplant indications for MDS/MPNs entities (excluding CMML) [3].

From: Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee

Entity

Transplant indications

aCML [ICC]/ MDS/MPN with neutrophilia[WHO]

All eligible patients should be considered for transplant early after diagnosis, with a prompt donor search.

MDS/MPN with SF3B1 mutation and thrombocytosis [WHO/ICC]

Transplant should be considered in high-risk eligible patients (e.g., refractory anemia, adverse cytogenetics, and/or ASXL1 or SETBP1 mutations), with a timely donor search. Standard MDS transplant guidelines should be followed regarding transplant platforms.

MDS/MPN with ring sideroblasts and thrombocytosis, NOS [ICC only]

Same indications as for MDS/MPN with SF3B1-mutated forms.

MDS/MPN, NOS [ICC/WHO]

All eligible patients should be considered for transplant early after diagnosis, particularly those with aggressive clinical behavior, rapid progression, or high-risk features. Standard CMML transplant guidelines could be applied regarding transplant platforms, recognizing the lack of a robust evidence base.

Back to article page